APVO
Aptevo Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+1.75%Sep 3, 2026, 18:25 UTC
Aptevo Therapeutics announced clinical trial results for its lead candidate mipletamig, reporting a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations.
Source:Aug 14, 2026, 12:05 UTC
Aptevo Therapeutics entered into a 50/50 collaboration with Niowave to develop radiopharmaceutical therapeutics.
Source:Aug 14, 2026, 12:05 UTC
Aptevo Therapeutics reported financial results for the quarter ended June 30, 2026, and provided a business update on its clinical programs and collaborations.
Source:Aug 12, 2026, 13:30 UTC
Aptevo Therapeutics entered into warrant inducement agreements with holders of existing warrants to exercise them in full for cash, raising $4.5 million gross proceeds, and will issue new inducement warrants.
Jul 27, 2026, 12:05 UTC
Aptevo Therapeutics filed a patent application for a Nectin-4 x PD-L1 dual-targeting backbone to support its solid tumor strategy.
Source:Jun 30, 2026, 12:05 UTC
Aptevo Therapeutics Inc. was awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for its APVO451 immunotherapy candidate.
Source: